BACKGROUND: Recent studies show that microRNAs (miRNAs), small non-coding RNAs that negatively regulate gene expression, may have potential for monitoring cancer status. We investigated circulating miRNAs in prostate cancer that may be associated with the progression of hormone-sensitive primary tumors to metastatic castration resistant prostate cancer (CRPC) after androgen deprivation therapy. METHODS: Using genome-wide expression profiling by TaqMan Human MicroRNA Arrays (Applied Biosystems) and/or quantitative real-time polymerase chain reaction, we compared the expression levels of miRNAs in serum samples from 28 patients of low-risk localized disease, 30 of high-risk localized disease and 26 of metastatic CRPC. RESULTS: We demonstrated that serum samples from patients of low risk, localized prostate cancer and metastatic CRPC patients exhibit distinct circulating miRNA signatures. MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. CONCLUSIONS: Circulating miRNAs, particularly miR-375, miR-141, miR-378*, and miR-409-3p, are differentially expressed in serum samples from prostate cancer patients. In the search for improved minimally invasive methods to follow cancer pathogenesis, the correlation of disease status with the expression patterns of circulating miRNAs may indicate the potential importance of circulating miRNAs as prognostic markers for prostate cancer progression.
BACKGROUND: Recent studies show that microRNAs (miRNAs), small non-coding RNAs that negatively regulate gene expression, may have potential for monitoring cancer status. We investigated circulating miRNAs in prostate cancer that may be associated with the progression of hormone-sensitive primary tumors to metastatic castration resistant prostate cancer (CRPC) after androgen deprivation therapy. METHODS: Using genome-wide expression profiling by TaqMan Human MicroRNA Arrays (Applied Biosystems) and/or quantitative real-time polymerase chain reaction, we compared the expression levels of miRNAs in serum samples from 28 patients of low-risk localized disease, 30 of high-risk localized disease and 26 of metastatic CRPC. RESULTS: We demonstrated that serum samples from patients of low risk, localized prostate cancer and metastatic CRPC patients exhibit distinct circulating miRNA signatures. MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. CONCLUSIONS: Circulating miRNAs, particularly miR-375, miR-141, miR-378*, and miR-409-3p, are differentially expressed in serum samples from prostate cancerpatients. In the search for improved minimally invasive methods to follow cancer pathogenesis, the correlation of disease status with the expression patterns of circulating miRNAs may indicate the potential importance of circulating miRNAs as prognostic markers for prostate cancer progression.
Authors: Jing Xiao; Ai-Yu Gong; Alex N Eischeid; Dongqing Chen; Caishu Deng; Charles Y F Young; Xian-Ming Chen Journal: Prostate Date: 2012-02-07 Impact factor: 4.104
Authors: Luke A Selth; Scott Townley; Joanna L Gillis; Aleksandra M Ochnik; Krisna Murti; Robyn J Macfarlane; Kim N Chi; Villis R Marshall; Wayne D Tilley; Lisa M Butler Journal: Int J Cancer Date: 2011-11-03 Impact factor: 7.396
Authors: Matthew N Poy; Lena Eliasson; Jan Krutzfeldt; Satoru Kuwajima; Xiaosong Ma; Patrick E Macdonald; Sébastien Pfeffer; Thomas Tuschl; Nikolaus Rajewsky; Patrik Rorsman; Markus Stoffel Journal: Nature Date: 2004-11-11 Impact factor: 49.962
Authors: B Zheng; L Liang; S Huang; R Zha; L Liu; D Jia; Q Tian; Q Wang; C Wang; Z Long; Y Zhou; X Cao; C Du; Y Shi; X He Journal: Oncogene Date: 2011-12-19 Impact factor: 9.867
Authors: Robert W Ross; Wanling Xie; Meredith M Regan; Mark Pomerantz; Mari Nakabayashi; Timothy J Daskivich; Oliver Sartor; Mary-Ellen Taplin; Philip W Kantoff; William K Oh Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall Journal: Nat Cell Biol Date: 2007-05-07 Impact factor: 28.824
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Philip A Gregory; Andrew G Bert; Emily L Paterson; Simon C Barry; Anna Tsykin; Gelareh Farshid; Mathew A Vadas; Yeesim Khew-Goodall; Gregory J Goodall Journal: Nat Cell Biol Date: 2008-03-30 Impact factor: 28.824
Authors: Alicia C McDonald; Jay D Raman; Jing Shen; Jason Liao; Bhavyata Pandya; Manish A Vira Journal: Urol Oncol Date: 2019-08-14 Impact factor: 3.498
Authors: Qizhi Zheng; Sarah B Peskoe; Judit Ribas; Fatema Rafiqi; Tarana Kudrolli; Alan K Meeker; Angelo M De Marzo; Elizabeth A Platz; Shawn E Lupold Journal: Prostate Date: 2014-09-22 Impact factor: 4.104
Authors: Xiaoyi Huang; Tiezheng Yuan; Meihua Liang; Meijun Du; Shu Xia; Rachel Dittmar; Dian Wang; William See; Brian A Costello; Fernando Quevedo; Winston Tan; Debashis Nandy; Graham H Bevan; Sherri Longenbach; Zhifu Sun; Yan Lu; Tao Wang; Stephen N Thibodeau; Lisa Boardman; Manish Kohli; Liang Wang Journal: Eur Urol Date: 2014-08-14 Impact factor: 20.096
Authors: Medha Darshan; Qizhi Zheng; Helen L Fedor; Nicolas Wyhs; Srinivasan Yegnasubramanian; Peng Lee; Jonathan Melamed; George J Netto; Bruce J Trock; Angelo M De Marzo; Karen S Sfanos Journal: Prostate Date: 2013-09-21 Impact factor: 4.104